SAN DIEGO, May 20, 2020 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today the expansion of its footprint into a new 14,000 square foot lab and office space, located at 10655 Sorrento Valley Road, Suite 100, in the Sorrento Valley biotech cluster of San Diego, CA.
"We are very excited to be one of the first biotech companies to move into this state-of-the art lab and office space, joining many other important companies in this emerging area," said Arthur T. Suckow, Co-Founder and CEO of DTx Pharma. "This new facility represents an important strategic step for DTx. It provides us with a solid foundation to grow our culture, expand our team and speed development and deployment of our fatty acid conjugate technology platform to solve the drug delivery challenges associated with RNA-based medicines."
DTx's new facility in Sorrento Valley, which was completed less than a year ago, will allow the company to internalize its chemistry efforts, broaden the application of its fatty acid conjugate technology, and expand its team and infrastructure to support the future growth of the company. DTx was launched in August 2017 and completed its $10.6M Series A in January 2020 with investment from FBV Fund I, Eli Lilly, Viva Biotech, ExSight Ventures and the Tech Coast Angels, among others.
About DTx Pharma
DTx Pharma, Inc. is a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease. The company's proprietary delivery technology platform utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body. In preclinical studies, DTx has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells and many other specialized cell types. Based upon the novelty, IP position and data demonstrating the effectiveness of its proprietary fatty acid motifs, DTx has previously received investment, nondilutive funding and other forms of support from Eli Lilly, Eye CRO and the CMT Research Foundation (CMTRF) for its ocular and muscle programs and has received multiple grant awards from the NIH (NCATS, NIA), and the TPEP program of Alzheimer's Association and Rainwater Charitable Foundation to advance its efforts to treat CNS diseases. To learn more about DTx Pharma, please visit www.dtxpharma.com and follow DTx on Twitter @DTxPharma.